Trial Profile
Baricitinib in Patients With Relapsing or naïve Dermatomyositis: a Multicenter Randomized Controlled Trial (BIRD)
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 27 Mar 2024
Price :
$35
*
At a glance
- Drugs Baricitinib (Primary) ; Azathioprine; Corticosteroids; Methotrexate; Prednisone
- Indications Dermatomyositis
- Focus Therapeutic Use
- Acronyms BIRD
- 06 Sep 2022 Planned End Date changed from 17 Mar 2026 to 28 Feb 2026.
- 06 Sep 2022 Planned primary completion date changed from 17 Mar 2026 to 28 Feb 2026.
- 22 Aug 2022 Planned End Date changed from 1 Dec 2025 to 17 Mar 2026.